QuidelOrthoQDEL
About: QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.
Employees: 7,100
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
123% more call options, than puts
Call options by funds: $15M | Put options by funds: $6.71M
43% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 69
42% more capital invested
Capital invested by funds: $2.28B [Q2] → $3.25B (+$965M) [Q3]
29% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 9 (+2) [Q3]
3.42% more ownership
Funds ownership: 102.56% [Q2] → 105.98% (+3.42%) [Q3]
5% less first-time investments, than exits
New positions opened: 55 | Existing positions closed: 58
1% less funds holding
Funds holding: 260 [Q2] → 257 (-3) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
UBS John Sourbeer 0 / 0 met price target | 38%upside $50 | Neutral Upgraded | 19 Sept 2024 |
Craig-Hallum Alexander Nowak 64% 1-year accuracy 9 / 14 met price target | 58%upside $57 | Buy Upgraded | 5 Sept 2024 |
Financial journalist opinion
Based on 10 articles about QDEL published over the past 30 days
